 |
Prospector
Profile
1107-05
|
| |
| Immunomedics, Inc. |
NAICS |
325413 |
| 300 American Rd.
Morris Plains, NJ 07950 |
Description |
Pharmaceuticals Mfg. |
| (973) 605-8200 |
Employees |
108 |
| http://www.immunomedics.com/ |
Revenue |
(mil) |
8.5060 |
| |
Income |
(mil) |
-16.6550 |
| |
Assets |
(mil) |
60.1980 |
| |
Liability |
(mil) |
39.8680 |
| |
(for the year ended 2007-06-30) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Immunomedics, Inc. had a net loss of $16,655,914 on revenues of $8,506,012 for the year ended June 30, 2007. This is much lower than the $28,560,476 net loss on revenues of $4,352,778 incurred during the year ended June 30, 2006, and the $26,559,002 net loss on revenues of $3,813,442 during the year ended June 30, 2005. As a result of its recurring losses, the Company has an accumulated deficit of $219,188,818 as of June 30, 2007.
|
| |
|
Intellectual Property:
The Company has accumulated a sizeable portfolio of patents and patent applications in the course of research, which constitutes a very valuable business asset. Some of these patents relate to diagnostic imaging products and product candidates, while others relate to therapeutic product candidates. As of August 31, 2007, this portfolio included 108 issued U.S. patents. In addition, the portfolio included more than 285 issued foreign patents, with a number of U.S. and foreign patent applications pending. The Company has also obtained licenses from various parties for rights to use proprietary technologies and compounds. The mark “IMMUNOMEDICS” is registered in the U.S. and 36 foreign countries and a European Community Trademark has been granted. The Company's other important trademarks include Immustrip, Cea-Scan, Leukoscan, Lymphoscan, Cea-Cide and Lymphocide. [SEC Filing 10-K 09-13-07]
|
| |
|
Description:
The Company engages in the development, manufacture and commercialization of diagnostic imaging and therapeutic products for the detection and treatment of cancer, autoimmune and other diseases.
|
| |
|
Officers:
David M. Goldenberg (Chair); Cynthia L. Sullivan (Pres., CEO & Dir.); Gerard G. Gorman (SVP); Marvin E. Jaffe (Dir.); Edward T. Wolynic (Dir.); Mary Paetzold (Dir.); Brian A. Markison (Dir.); Don C. Stark (Dir.)
|
| |
|
Auditor:
Ernst & Young LLP
|
| |
|
Securities:
Common Stock-Symbol IMMU; NasdaqGM;
75,062,164 common shares outstanding as of September 7, 2007.
|
| |
| |
| |
| return to main page |
|
|
